Glyburide in Pregnancy: 2026 Safety Update & Alternatives

Through the 2000s and 2010s, glyburide (also called glibenclamide outside the US) was widely prescribed as an oral alternative to insulin for gestational diabetes. It seemed simple, effective, and patient-friendly—no injections required. But the evidence has turned significantly against it, and 2025-2026 data has cemented what many clinicians suspected: glyburide should not be the first-choice oral agent for gestational diabetes. Here's what you need to know.

What Is Glyburide?

Glyburide is a sulfonylurea—a class of drugs that stimulates the pancreas to produce more insulin. It was one of the first oral diabetes medications, approved for type 2 diabetes in the 1980s. Its appeal for gestational diabetes came from a landmark 2000 NEJM study by Langer et al., which suggested it was as effective as insulin and did not significantly cross the placenta.

Both of those findings have been substantially revised by subsequent research.

The Current Safety Evidence (2025-2026)

The Neonatal Outcome Data

The most important safety concern with glyburide is its impact on newborns. A 2025 systematic review and meta-analysis published in Frontiers in Pediatrics and related analyses have shown that compared to insulin:

• Newborns of glyburide-treated mothers have higher rates of NICU admission
• Neonatal hypoglycemia is significantly more common (glyburide crosses the placenta and causes the fetal pancreas to produce excess insulin)
• Respiratory distress in newborns is elevated
• Large for gestational age (macrosomic) births are more frequent than with insulin
• Birth injury (related to larger birth size) is more common

A key analysis found that glyburide was "not noninferior to insulin" based on a composite outcome of neonatal hypoglycemia, macrosomia, and hyperbilirubinemia—a formal statistical test showing glyburide performed meaningfully worse.

Placental Transfer Findings

Early studies reported minimal glyburide placental transfer. Subsequent research using more sensitive detection methods found that glyburide is detectable in umbilical cord blood at levels representing approximately 50-70% of maternal levels. This direct fetal exposure:

• Stimulates the fetal pancreas directly
• Can cause fetal insulin excess, driving fetal fat deposition (macrosomia)
• Causes neonatal hypoglycemia when the drug supply abruptly ends at delivery

The Efficacy Problem

Beyond safety, glyburide has a higher treatment failure rate than initially reported:

• In contemporary studies, 20-30% of women started on glyburide require supplemental or replacement insulin
• Glyburide efficacy decreases as gestational age advances and placental hormonal insulin resistance increases
• Women with higher baseline glucose levels are more likely to fail glyburide monotherapy

What the 2026 Guidelines Say

ADA 2026 Standards

The 2026 ADA Standards of Care state clearly:

"These agents (glyburide and other sulfonylureas) are not recommended as first-line treatment of gestational diabetes mellitus because they are known to cross the placenta and data on long-term safety for offspring is of some concern."

This represents a significant shift from even 5 years ago, when glyburide was listed as an alternative option without this level of explicit caution.

ACOG Position

ACOG has similarly moved away from glyburide, noting that insulin and metformin are the preferred pharmacological options. While ACOG acknowledges glyburide may be used in specific circumstances, it is no longer considered an equivalent first-line alternative.

A Brief History: How Glyburide Became Common (Then Fell Out of Favor)

The Rise (2000-2010)

The 2000 Langer et al. NEJM study was enthusiastically received: 93 glyburide-treated women showed outcomes comparable to 92 insulin-treated women, with reported minimal placental transfer. The oral administration was seen as patient-friendly and cost-effective. Glyburide use for GD grew rapidly.

The Questions (2010-2020)

Larger observational studies and subsequent RCTs began showing less favorable results. Questions arose about the accuracy of the initial placental transfer data. Meta-analyses incorporating more trials showed glyburide underperformed insulin on multiple outcomes.

The Evidence Consolidates (2020-2026)

More rigorous studies, better placental transfer detection methods, and formal meta-analyses confirmed the safety concerns. The 2026 ADA guidelines reflect this accumulated evidence with explicit discouragement of glyburide as first-line therapy.

The Better Alternatives in 2026

Option 1: Insulin — First-Line Choice

Insulin remains the gold standard for pharmacological GD management:

• Does not cross the placenta
• Decades of safety data in pregnancy
• Can be titrated precisely to glucose levels
• Multiple formulations available (rapid-acting for meals, long-acting for basal control)
• Modern insulin delivery devices (pens, needles) have minimized the burden of injections

The primary barrier to insulin—needle phobia and injection burden—is real and deserves acknowledgment. But with proper training and support, most women adapt well. CGM use alongside insulin also reduces hypoglycemia risk, which is the main insulin side effect to manage.

Option 2: Metformin — Second-Line Oral Alternative

For women who decline insulin, metformin is the preferred oral alternative:

• No injection required
• Lower hypoglycemia risk than glyburide
• Does not cause the neonatal outcomes seen with glyburide
• Substantially higher patient preference rates vs. insulin
• Lower cost than insulin

As discussed in our metformin vs. insulin article, metformin does cross the placenta, and long-term offspring follow-up data raises some concerns about childhood adiposity in some cohorts. These concerns are distinct from and less immediately serious than glyburide's neonatal outcomes.

If You Were Prescribed Glyburide

If your healthcare provider has prescribed glyburide for gestational diabetes, you have a right to understand the evidence and discuss alternatives. Here's how to approach that conversation:

1. Ask why glyburide was chosen over insulin or metformin given the current evidence
2. Reference the 2026 ADA Standards, which explicitly discourage glyburide as first-line therapy
3. Ask about neonatal monitoring: if glyburide is continued, ensure your baby will be closely monitored for hypoglycemia after birth
4. Request a specialist consultation if your provider is unwilling to discuss alternatives—an endocrinologist or maternal-fetal medicine specialist will be current on this evidence

Special Circumstances Where Glyburide Might Still Appear

While guidelines have moved clearly away from glyburide, it may still appear in some contexts:

• Resource-limited settings: Where insulin is unavailable or prohibitively expensive
• Late-trimester diagnosis: Some providers use glyburide for very mild, late-diagnosed GD where treatment duration is short
• Insulin refusal: For a patient who refuses insulin and also does not tolerate metformin, glyburide represents the last oral option

In all such cases, enhanced neonatal monitoring for hypoglycemia should be planned.

Monitoring for Glyburide Side Effects During Pregnancy

If you are on glyburide, monitor closely for:

• Maternal hypoglycemia (low blood sugar symptoms: shakiness, sweating, confusion)
• Signs of macrosomia on ultrasound (baby measuring large for gestational age)
• Ensure your delivery team knows you were on glyburide so they can monitor your newborn's blood sugar closely for 24-48 hours after birth

For more on gestational diabetes medication options, see our metformin vs. insulin 2026 guide and the overview of 2026 GD guidelines.

This content is for informational purposes only and is not medical advice. Always consult your healthcare provider or registered dietitian for personalized guidance.